Dermatomyositis Market to Witness Growth by 2032, Estimates DelveInsight | Alexion Pharmaceuticals, AstraZeneca, Argenx, Pfizer, Janssen, Corbus Pharmaceuticals, Kezar Life Sciences

 Breaking News
  • No posts were found

Dermatomyositis Market to Witness Growth by 2032, Estimates DelveInsight | Alexion Pharmaceuticals, AstraZeneca, Argenx, Pfizer, Janssen, Corbus Pharmaceuticals, Kezar Life Sciences

February 24
10:53 2023
Dermatomyositis Market to Witness Growth by 2032, Estimates DelveInsight | Alexion Pharmaceuticals, AstraZeneca, Argenx, Pfizer, Janssen, Corbus Pharmaceuticals, Kezar Life Sciences
Dermatomyositis Market

DelveInsight’s Dermatomyositis Market Insights report includes a comprehensive understanding of current treatment practices, dermatomyositis emerging drugs, market share of individual therapies, and current and forecasted market size from 2019 to 2032, segmented into 7MM [the United States, the EU-4 (Italy, Spain, France, and Germany), the United Kingdom, and Japan].


Key Takeaways from the Dermatomyositis Market Report

  • As per DelveInsight analysis, the dermatomyositis market size in the 7MM was approximately USD 175 million in 2021.
  • According to the assessment done by DelveInsight, the estimated total dermatomyositis prevalent population in the 7MM was approximately 61K in 2021. 
  • Globally, leading dermatomyositis companies such as Priovant Therapeutics, CSL Behring, Alexion Pharmaceuticals, AstraZeneca, Argenx, Pfizer, Janssen, Corbus Pharmaceuticals, Kezar Life Sciences, Horizon Therapeutics, PAEAN Biotechnology, and others are developing novel dermatomyositis drugs that can be available in the dermatomyositis market in the coming years.
  • The promising dermatomyositis therapies in the pipeline include brepocitinib, HIZENTRA (immune globulin), ULTOMIRIS (ravulizumab), efgartigimod PH20, PF-06823859 , and others.


Discover which therapies are expected to grab the major dermatomyositis market share @ Dermatomyositis Market Insight


Dermatomyositis Overview

Dermatomyositis is a rare inflammatory disease with distinctive cutaneous findings and varying degrees of systemic involvement; it can occur in both juvenile and adult forms. Adult and juvenile dermatomyositis share pathognomic skin rash and muscle inflammation, but they are distinct diseases with unique disease features and complications.

While the clinical presentation of JDM differs from that of adults, the skin lesions are similar, except for an increased incidence of calcinosis cutis in juvenile patients. Low-grade fever, an increased risk of gastrointestinal manifestations, and symmetric arthritis of the large and small joints are all common findings.

The underlying cause of dermatomyositis is unknown; however, evidence suggests that genetic, immune, and environmental factors all play a role. A detailed patient history, thorough clinical examination, detection of characteristic physical findings, and certain specialized tests are used to make the diagnosis. Creatinine kinase levels are less likely to be elevated in JDM than in adult dermatomyositis.


Dermatomyositis Epidemiology Segmentation

  • DelveInsight estimates that there were approximately 61K prevalent cases of dermatomyositis in the 7MM in 2021.
  • Among the EU4 and the UK, the highest number of prevalent cases of DM were in Germany, i.e., ~4,900 cases in the year 2021, which are estimated to rise by 2032.

The dermatomyositis market report proffers epidemiological analysis for the study period 2019–2032 in the 7MM segmented into:

  • Total Prevalent Cases
  • Total Diagnosed Prevalent Cases
  • Gender-specific Diagnosed Prevalent Cases
  • Age-specific Diagnosed Prevalent Cases
  • Severity-specific Diagnosed Prevalent Cases
  • Classification-Specific Diagnosed Prevalent Cases
  • Chronicity-Specific Diagnosed Prevalent Cases
  • Co-morbidity-Specific Diagnosed Prevalent Cases
  • Treated Cases


Download the report to understand which factors are driving dermatomyositis epidemiology trends @ Dermatomyositis Epidemiological Insights


Dermatomyositis Treatment Market 

The goal of dermatomyositis treatment is to decrease inflammation and vasculitis, as well as to reduce symptomatology and improve the patient’s quality of life. To accomplish this goal, a dermatomyositis treatment regimen must be initiated early in the disease process and will necessitate an interprofessional approach to therapy. The administration of steroids is used to treat dermatomyositis. A high prednisolone dose must also be started early to improve muscle weakness. Steroid therapy should relieve symptoms within 4 weeks, after which the steroid dosage should be gradually tapered to 1 mg/kg every other day over a 10-week period. When prednisone is not an option, second-line agents such as methotrexate and azathioprine may be used.

Patients who develop resistance to therapy may benefit from rituximab, IVIG, and other biologics . Antipruritics, topical steroids, hydroxychloroquine, and steroids may be used to treat superficial skin diseases. The FDA approved OCTAGAM 10% , a 10% solution of intravenous human immunoglobulin (IVIG), to treat adults with diabetes last year. The approval was based on the findings of the Progress in Dermatomyositis (ProDERM) study. More recently, the FDA Office of Orphan Product Development granted Octapharma, the manufacturer of OCTAGAM 10%, 7 years of marketing exclusivity for this product, which is the first and only IVIG treatment for adult dermatomyositis.


To know more about dermatomyositis treatment guidelines, visit @ Dermatomyositis Treatment Scenario


Dermatomyositis Pipeline Therapies and Key Companies

  • Brepocitinib: Priovant Therapeutics
  • HIZENTRA (immune globulin): CSL Behring
  • ULTOMIRIS (ravulizumab): Alexion Pharmaceuticals/AstraZeneca
  • Efgartigimod PH20: Argenx
  • PF-06823859: Pfizer
  • Nipocalimab: Janssen


Learn more about the FDA-approved drugs for dermatomyositis @ Drugs for Dermatomyositis Treatment  


Dermatomyositis Market Dynamics

The dynamics of the dermatomyositis market is anticipated to change in the future due to the improvement in the rise in the number of healthcare spending across the world and rising cases of dermatomyositis . Moreover, There has been a significant increase in knowledge and understanding of diabetes in recent years, which is increasingly being considered when making therapeutic decisions . Better prognostic markers would allow physicians to diagnose and treat at the onset of disease, potentially preventing disease progression. In addition, R&D to understand the diversity of the disease may improve diagnosis.  


Scope of the Dermatomyositis  Market Report

  • Therapeutic Assessment: Dermatomyositis current marketed and emerging therapies
  • Dermatomyositis Market Dynamics:  Dermatomyositis market drivers and barriers 
  • Competitive Intelligence Analysis:  SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
  • Unmet Needs, KOL’s views, Analyst’s views, Dermatomyositis Market Access and Reimbursement


Discover more about dermatomyositis drugs in development @ Dermatomyositis Clinical Trials


Table of Contents

1.  Dermatomyositis Market Key Insights

2.  Dermatomyositis Market Report Introduction

3.  Dermatomyositis Market Overview at a Glance

4.  Dermatomyositis Market Executive Summary

5.  Disease Background and Overview

6.  Dermatomyositis Treatment and Management

7.  Dermatomyositis Epidemiology and Patient Population

8.  Patient Journey

9.  Dermatomyositis Marketed Drugs

10. Dermatomyositis Emerging Drugs

11. Seven Major Dermatomyositis Market Analysis

12. Dermatomyositis Market Outlook

13. Potential of Current and Emerging Therapies

14. KOL Views

15. Dermatomyositis Market Drivers

16. Dermatomyositis Market Barriers

17. Unmet Needs

18. SWOT Analysis

19. Appendix

20. DelveInsight Capabilities

21. Disclaimer

22. About DelveInsight

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Ankit Nigam
Email: Send Email
Phone: +19193216187
Address:304 S. Jones Blvd #2432
City: Albany
State: New York
Country: United States